Annovis Bio Inc. (ANVS) Social Stream



Annovis Bio Inc. (ANVS): $6.69

0.15 (+2.29%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Featured Post From StockTwits About ANVS

$ANVS I'm not good at English, I ask for your understanding. In my opinion, ANVS will be difficult to be granted as Orphan Drug Designation.
Because the population of people with Down syndrome in the U.S. is over 200,000(It has been estimated to be over 400,000). You can find easily that data in google.
No need to be disappointed, because ANVS401 still saw statistically significant changes (p<0.05) in ADAS-Cog11, MDSUPDRS and WAIS, showing efficacy of the drug in AD and PD patents. absolutely worth it.
The time is on our side.
kagaforever, published August 17, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!